Author:
Askari Mozhde,Mirmosayyeb Omid,Ghaffary Elham Moases,Ghoshouni Hamed,Shaygannejad Vahid,Ghajarzadeh Mahsa
Subject
Neurology (clinical),Neurology,General Medicine
Reference56 articles.
1. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients;Alping;Ann. Neurol.,2020
2. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions;Bartholomäus;Nature,2009
3. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab;Bianco;Eur. Neurol.,2015
4. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;Lancet Neurol.,2014
5. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis;Cohen;N. Engl. J. Med.,2010
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献